Company: IMNN
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022120
Chunk: 37

Company: Imunon, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 8
Chunk 37
---
 program and other potential funding sources The Company may not be able to obtain funding on acceptable terms,
or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders. The Company’s
ability to raise additional funds will depend, among other factors, on financial, economic and market conditions, many of which are outside
of its control, and it may be unable to raise financing when needed, or on terms favorable to the Company. If the Company is unable to
obtain sufficient capital to fund its operations it may be required to evaluate alternatives. The Company’s financial statements
do not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount and classification
of liabilities that may be required should the Company be unable to continue as a going concern.

27

As
a result of the risks and uncertainties discussed in the 2024 Annual Report filed on February 27, 2025 with the SEC, among others, we
are unable to estimate the duration and completion costs of our research and development projects or when, if ever, and to what extent
we will receive cash inflows from the commercialization and sale of a product if one of our drug candidates receives regulatory approval
for marketing, if at all. Our inability to complete any of our research and development activities, preclinical studies or clinical trials
in a timely manner or our failure to enter into collaborative agreements when appropriate could significantly increase our capital requirements
and could adversely impact our liquidity. While our estimated future capital requirements are uncertain and could increase or decrease
as a result of many factors, including the extent to which we choose to advance our research and development activities, preclinical
studies and clinical trials, or whether we are in a position to pursue manufacturing or commercialization activities, we will need significant
additional capital to progress our drug candidates through development and clinical trials, obtain regulatory approvals and manufacture
and commercialize approved products, if any. We do not know whether we will be able to access additional capital when needed or on terms
favorable to us or our stockholders. Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would
jeopardize the future success of our business.

Financing
Overview

Equity,
Debt and Other Forms of Financing

During
2025 and 2024 (through the date of this Quarterly Report on Form 10-Q), we issued a total of 0.4 million shares of common stock as